# COVID-19

COVID-19

emerging communicable disease, atypical pneumonia, class of disease| Official name | coronavirus disease  |
| Short name | COVID-19  |
| Significant person | Zhang Jixian, Zhong Nanshan  |
| Significant event | COVID-19 pandemic  |
| Has cause | SARS-CoV-2  |
| Time of discovery anaa invention | December 2019  |
| Location of discovery | Wuhan  |
| Health specialty | infectious diseases, pulmonology, virology, epidemiology, emergency medicine  |
| Medical examination | reverse transcription polymerase chain reaction, ELISA, computed tomography, polymerase chain reaction, COVID-19 rapid antigen test  |
| Hashtag | COVID19  |
| Has natural reservoir | mink  |
| Get characteristic | contagiousness, COVID-19 mortality  |
| History of topic | timeline of the COVID-19 pandemic  |
| Subject has role | acute respiratory distress syndrome  |
| Manifestation of | disease X  |
| Handled, mitigated, or managed by | treatment of COVID-19  |
| EntitySchema for this class | Entity schema not supported yet (E196)  |

**Coronavirus disease 2019** (**COVID-19**, dem sanso know am as SARS-2) be a contagious disease wey be caused by de coronavirus SARS-CoV-2. Insyd January 2020, na de disease spread worldwide, wey result in de COVID-19 pandemic.

De symptoms of COVID‑19 fi vary buh often dey include fever, fatigue, cough, breathing difficulties, loss of smell, den loss of taste. Symptoms fi begin one to fourteen days after exposure to de virus. At least a third of people wey be infected no dey develop noticeable symptoms. Of those wey develop symptoms noticeable enough make dem be classified as patients, chaw (81%) dey develop mild to moderate symptoms (up to mild pneumonia), while 14% dey develop severe symptoms (dyspnea, hypoxia, anaa more dan 50% lung involvement on imaging), den 5% dey develop critical symptoms (respiratory failure, shock, anaa multiorgan dysfunction). Older people get a higher risk of dem dey develop severe symptoms. Sam complications dey result in death. Sam people continue dey experience a range of effects (long COVID) for months anaa years after infection, wey na dem observe damage. Multi-year studies for de long-term effects dey go on.

Testing methods for COVID-19 make dem detect de virus ein nucleic acid dey include real-time reverse transcription polymerase chain reaction (RT‑PCR), transcription-mediated amplification, den reverse transcription loop-mediated isothermal amplification (RT‑LAMP) from a nasopharyngeal swab.

## Read further

* "Progress report on the coronavirus pandemic". *Nature*. **584** (7821): 325. 1 August 2020. doi:10.1038/D41586-020-02414-1. ISSN 1476-4687. PMID 32814893. Wikidata Q98568681.
* COVID-19 infection prevention and control measures for primary care, including general practitioner practices, dental clinics and pharmacy settings: first update. *European Centre for Disease Prevention and Control (ECDC)* (Report). October 2020.
* Erola Pairo-Castineira, Sara Clohisey, Lucija Klarić, Andrew Bretherick, Konrad Rawlik, Dorota Pasko, et al. (11 December 2020). "Genetic mechanisms of critical illness in Covid-19". *Nature*. doi:10.1038/S41586-020-03065-Y. ISSN 1476-4687. PMID 33307546. Wikidata Q104287299. Scholia Q104287299.

### Health agencies

* Coronavirus disease (COVID‑19) Facts by de World Health Organization (WHO)
* Coronavirus (COVID‑19) by de UK National Health Service (NHS)
* Coronavirus 2019 (COVID-19) by de US Centers for Disease Control and Prevention (CDC)

### Directories

* Coronavirus Resource Center at de Center for Inquiry
* COVID‑19 Information on FireMountain.net Archived 13 January 2022 at the Wayback Machine
* COVID‑19 Resource Directory on OpenMD

### Medical journals

* BMJ's Coronavirus (covid‑19) Hub by de BMJ
* Coronavirus (Covid‑19) by *The New England Journal of Medicine*
* Coronavirus (COVID‑19) Research Highlights by Springer Nature
* Coronavirus Disease 2019 (COVID‑19) by *JAMA*
* COVID‑19 Resource Centre by *The Lancet*
* Covid‑19: Novel Coronavirus Archived 24 September 2020 at the Wayback Machine by Wiley Publishing
* Novel Coronavirus Information Center by Elsevier

### Treatment guidelines

* "Bouncing Back From COVID-19: Your Guide to Restoring Movement" (PDF). *Johns Hopkins Medicine*.
* "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines" (PDF). *National Institutes of Health*.
* "Guidelines on the Treatment and Management of Patients with COVID-19". *Infectious Diseases Society of America*.
* "JHMI Clinical Recommendations for Available Pharmacologic Therapies for COVID-19" (PDF). Johns Hopkins Medicine.
* NHS England and NHS Improvement. National Guidance for post-COVID syndrome assessment clinics (Report).
* World Health Organization (2022). Therapeutics and COVID-19: living guideline, 14 January 2022 (Report). hdl:10665/351006. WHO/2019-nCoV/therapeutics/2022.1.